QIAGEN N.V. (NYSE:QGEN) acquired N-of-One, Inc. for $26 million on January 4, 2019. The cash consideration, net of cash acquired totaled $24.4 million. The acquisition included contingent consideration which is recorded as part of the purchase price based on the acquisition date fair value. As part of the transaction, N-of-One’s technology-enabled, yet human-driven, services and the proprietary MarkerMine™ database are planned to be integrated into QIAGEN Clinical Insight. The transaction was financed from the existing cash reserves of QIAGEN. N-of-One is not expected to provide a material contribution to QIAGEN’s results in 2019. QIAGEN N.V. (NYSE:QGEN) completed the acquisition of N-of-One, Inc. on January 4, 2019.